title: Peanut agglutinin in combination with CD19 monoclonal antibody has potential as a purging agent in myeloma.
abstract: Administration of high-dose chemotherapy to patients with myeloma, followed by rescue with autologous bone marrow transplantation (ABMT), sometimes induces complete disease remission but relapse is usual. We have attempted to reduce the risk of relapse by selective in vitro removal of myeloma cells from the autologous graft. A combination of the (gal-galNac)-binding lectin peanut agglutinin (PNA), which binds all plasma cells, and the pan-B monoclonal antibody CD19 was assessed for purging marrow of myeloma cells and their putative precursors using a magnetic bead method. Preliminary experiments performed on peripheral blood mononuclear cells spiked with fluorescent-labeled PNA+ Kirk tumor cells showed that a magnetic bead: target cell ratio of 40:1 resulted in a greater than 3-log reduction in PNA+ cells. This technique was then applied to 17 samples of myeloma bone marrow and to 18 samples of normal bone marrow spiked with PNA+ Kirk cells and CD19+ hairy cell leukemia cells. In each case all detectable plasma cells and CD19+ lymphocytes were effectively removed, and normal hemopoietic progenitor cell recovery was greater than 55%. This purging system deserves further study as a means of reducing relapse rates in myeloma patients treated by a combination of high-dose chemotherapy and ABMT.
authors.affiliation: Department of Haematology, Liverpool University, England.
authors.forename: E G
authors.initials: EG
authors.lastname: Rhodes
authors.forename: P
authors.initials: P
authors.lastname: Baker
authors.forename: J M
authors.initials: JM
authors.lastname: Rhodes
authors.forename: J M
authors.initials: JM
authors.lastname: Davies
authors.forename: J C
authors.initials: JC
authors.lastname: Cawley
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D015703:Antigens, CD / Q000276:immunology*; D018941:Antigens, CD19; D000944:Antigens, Differentiation, B-Lymphocyte / Q000276:immunology*; D001402:B-Lymphocytes / Q000166:cytology; D001853:Bone Marrow / Q000502:physiology; D016026:Bone Marrow Transplantation / Q000379:methods*; D002469:Cell Separation; D003131:Combined Modality Therapy; D006410:Hematopoiesis; D006801:Humans; D066298:In Vitro Techniques; D037102:Lectins / Q000627:therapeutic use*; D008280:Magnetics; D009101:Multiple Myeloma / Q000628:therapy*; D019887:Peanut Agglutinin
chemical_list: D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D018941:Antigens, CD19; D000944:Antigens, Differentiation, B-Lymphocyte; D037102:Lectins; D019887:Peanut Agglutinin